Details for New Drug Application (NDA): 211724
✉ Email this page to a colleague
The generic ingredient in CAPECITABINE is capecitabine. There are twenty-eight drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the capecitabine profile page.
Summary for 211724
Tradename: | CAPECITABINE |
Applicant: | Reliance Life |
Ingredient: | capecitabine |
Patents: | 0 |
Pharmacology for NDA: 211724
Mechanism of Action | Nucleic Acid Synthesis Inhibitors |
Medical Subject Heading (MeSH) Categories for 211724
Suppliers and Packaging for NDA: 211724
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
CAPECITABINE | capecitabine | TABLET;ORAL | 211724 | ANDA | Chartwell RX, LLC | 62135-783 | 62135-783-60 | 60 TABLET in 1 BOTTLE (62135-783-60) |
CAPECITABINE | capecitabine | TABLET;ORAL | 211724 | ANDA | Chartwell RX, LLC | 62135-784 | 62135-784-12 | 120 TABLET in 1 BOTTLE (62135-784-12) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 150MG | ||||
Approval Date: | Apr 27, 2020 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 500MG | ||||
Approval Date: | Apr 27, 2020 | TE: | AB | RLD: | No |
Complete Access Available with Subscription